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Continuing a highly successful series of meetings originally
established by Angelika Görg in Munich, scientists gathered
for the first Proteomic Forum in Berlin. The five-day
meeting organized by the German Society of Proteome
Research included plenary lectures, poster sessions and
workshops focusing on new developments in the field of
proteome science. With about 500 participants, 60 speakers
and 100 company representatives, the meeting provided a
broad overview of the field. While virtually all areas of
proteomics were presented, a clear trend towards mass
spectrometry-based workflows was evident. Featured topics
discussed in this report include proteomic techniques,
biomarker discovery, proteomics of molecular machines and
cell signaling.
P Pr ro ot te eo om mi ic c   t te ec ch hn ni iq qu ue es s
The increased mass accuracy, dynamic range, speed and
sensitivity of mass spectrometers is currently the driving
force for the rapid expansion in the number and quality of
proteomic datasets. As the depth of proteome coverage
increases, obtaining quantitative data becomes increasingly
more important. Hence, quantitative proteomics was a
common theme of the meeting, with methods ranging from
simple spectral counting to stable isotope labeling-based
approaches, such as stable isotope labeling with amino acids
in cell culture (SILAC). John Yates III (The Scripps Research
Institute, CA, USA) presented data on the use of spectral
counting for label-free quantification to investigate the
interactome of the cystic fibrosis transmembrane conduc-
tance regulator (CFTR). Importantly, quantification facili-
tates differentiation between specific interaction partners and
non-specific contaminants, as well as assessment of the effect
of drugs on the interactome. Yates also presented 15N labeling
of rats as another approach for in vivo quantification.
Christoph Turk (Max Planck Institute of Psychiatry, Munich,
Germany) added a word of caution to this, as he found that
15N labeling of mice significantly affects animal behavior.
A new advancement for targeted proteomics was presented
by Ruedi Aebersold (Swiss Federal Institute of Technology
(ETH) Zurich, Switzerland). In an effort to expand the use of
multiple reaction monitoring (MRM) for proteomic pur-
poses, the group used data from large-scale identifications
and arrays of synthesized peptides to generate a library of
key MRM transitions for all yeast proteins. These transitions
can be used to identify and quantify, by MRM techniques,
proteins expressed at only 50 copies per cell. A number of
groups presented new bioinformatics approaches for the
prediction of MRM transitions based solely on sequence
information.
Several other approaches were presented that extend the
analytic abilities of mass spectrometry-based workflows. For
example, Kris Gevaert and Joel Vandekerckhove (Ghent
University, Belgium) reported on the use of combined
fractional diagonal chromatography (COFRADIC) for the
identification of protease target sites. Albert Heck (Nether-lands Proteomics Centre, Utrecht University, The Netherlands)
demonstrated that using the protease Lys-N in combination
with electron transfer dissociation (ETD) greatly facilitates
de novo sequencing of peptides and identification of post-
translational modifications.
B Bi io om ma ar rk ke er rs s
Identifying reliable markers indicative of a disease state
from body fluids has been reported to be a very daunting
task. As proteomic technologies have improved considerably
over recent years, the quest for biomarkers is becoming
popular again. A particularly promising source for potential
biomarkers is the secretome of diseased cells. Many cells
also release membranous vesicles (exosomes) that may
provide diagnostic information. Richard Simpson (Ludwig
Institute for Cancer Research, Melbourne, Australia) used
secretome data to identify proteins that are possibly indica-
tive of colon cancer. Thomas Conrads (University of Pitts-
burgh, PA, USA) described a similar approach for the identi-
fication of new biomarkers for prostate cancer. Richard
Caprioli (Vanderbilt University, TN, USA) reported on the
use of imaging matrix-assisted laser desorption ionization
(MALDI) to analyze biopsies obtained from cancer patients.
The spatial resolution of his data reveals that tumor markers
sometimes extend beyond the tumor margin into seemingly
healthy adjacent tissue. This indicates that surgical margins
may need to be reconsidered in some cases.
M Mo ol le ec cu ul la ar r   m ma ac ch hi in ne es s   a an nd d   p pr ro ot te ei in n   i in nt te er ra ac ct ti io on ns s
The analysis of complex molecular machines was the focus
of two sessions at the meeting. Several studies presented
employed a proteomic description of a complex, and deduced
substructures for analysis with more traditional methods.
Reinhard Lührmann (Max Planck Institute for Biophysical
Chemistry, Goettingen, Germany) presented work on yeast
and human spliceosomes revealing a high-resolution map of
the active complexes. The proteomic data nicely defined
subcomplexes, such as the NineTeen subcomplex of the
spliceosome. In collaboration with Henning Urlaub, the
group used a combination of mass spectrometry and UV
crosslinking to identify interacting complexes within the
spliceosome. Another long-standing goal is to use protein
interaction data to understand disease phenotypes. Marius
Ueffing (Helmholtz Zentrum Munich, Germany) used
tandem affinity purification to define the interactome of
lebercilin, a protein genetically linked to a severe form of
blindness. Interestingly, the identified interaction partners
linked the disease to vesicular transport, highlighting new
candidate disease genes.
K Ki in na as se e   s si ig gn na al li in ng g
Large-scale identification of phosphorylation sites is another
important dimension in proteomics. Roland Annan
(SmithKline Beecham Pharmaceuticals, PA, USA) and Ole
Jensen (University of Southern Denmark, Odense, Den-
mark) presented a number of new techniques used for the
identification of new phosphorylation sites in complex
mixtures. The use of affinity matrices, special precipitation
techniques and novel chromatographic strategies, such as
hydrophilic interaction liquid chromatography (HILIC),
proved to be particularly valuable. Combined with SILAC-
based quantification, these methods allowed for a systematic
comparison of the phosphoproteome of drug-resistant and
drug-sensitive breast cancer cells. These data may facilitate a
rational selection of chemotherapeutic agents to treat
cancer. As Boris Macek (Proteome Center Tübingen,
Germany) pointed out, large-scale SILAC-based quanti-
fication of phosphorylation is not limited to eukaryotes, but
also reveals that phosphorylation is dynamically regulated in
prokaryotes.
One problem in large-scale mapping of phosphorylation
sites is that this method alone cannot reveal direct kinase-
substrate relationships. Two groups showed that so-called
analog-sensitive kinases can be employed to alleviate this
problem. Hendrik Daub (Max Planck Institute of Bio-
chemistry, Martinsried, Germany) used a modified form of
Plk1 designed to respond to a specific inhibitory compound.
Cells expressing either this analog-sensitive kinase or wild-
type Plk1 were treated with the inhibitor. SILAC-based
quantification of phosphopeptides from both conditions
allowed identification of likely direct Plk1 substrates.
C Co on nc cl lu ud di in ng g   r re em ma ar rk ks s
The meeting provided an interesting snapshot of current
approaches and questions in proteomic science. As a forum
in the best sense of the word, the Proteomic Forum provided
a public space for many fruitful discussions. Given the
current speed at which the field is evolving, reviving the
meeting series was a logical consequence and proved to be a
great success. The improved analytic abilities of modern
instruments are beginning to transform basic research and
will have an impact on clinical proteomics. Ultimately, this
may bring mass spectrometers to the doctor’s office - the
dream of early pioneers like John Fenn.
A Ab bb br re ev vi ia at ti io on ns s
CFTR, cystic fibrosis transmembrane conductance regulator; COFRADIC,
combined fractional diagonal chromatography; ETD, electron transfer dis-
sociation; HILIC, hydrophilic interaction liquid chromatography; MALDI,
matrix-assisted laser desorption ionization; MRM, multiple reaction moni-
toring; SILAC, stable isotope labeling with amino acids in cell culture.
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